Oslo, Norway, 6 November 2013 - Algeta ASA (OSE: ALGETA), a company focused on the development of novel targeted cancer therapeutics, announces its financial calendar for 2014:

4th Quarter Results 2013:     28 February 2014
1st Quarter Results 2014:     22 May 2014
2nd Quarter Results 2014:    21 August 2014
3rd Quarter Results 2014:     20 November 2014

Annual General Meeting:        29 April 2014

All dates are tentative and could be subject to change.

###

For further information, please contact:

Mike Booth +1 646 410 1884
Communications & Corporate Affairs ir@algeta.com
Media enquiries:
Mark Swallow +44 207 638 9571
Citigate Dewe Rogerson mark.swallow@citigatedr.co.uk
Knut Ekern +47 22 04 82 00
Gambit Hill & Knowlton knut.ekern@hkstrategies.com
Kari Watson +1 781 235 3060
MacDougall Biomedical Communications kwatson@macbiocom.com
Investor enquiries:
Tricia Truehart +1 646 378 2953
The Trout Group t truehart@troutgroup.com

About Algeta

Algeta is a company focused on developing, manufacturing and marketing novel targeted therapies for patients with cancer. The Company is headquartered in Oslo, Norway, and has a US subsidiary, Algeta US, LLC, based in Cambridge, MA performing commercial marketing operations in the US. Algeta is listed on the Oslo Stock Exchange (Ticker: ALGETA). For more information please visit www.algeta.com.

This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

distributed by